Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Russell Horning

Nurse Practitioner, Psychiatric/Mental Health Phoenix, AZ Nurse Practitioner

NPI 1669526158 CMS profile 10763209

16620 N 40Th St Ste H4, Phoenix, AZ 85032

Open in the dashboard

General payments

$254,130

814 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Horning of Phoenix, AZ is reported in the CMS Open Payments database as having received $254,130 across 814 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,336 148
2024 General $42,408 215
2023 General $45,022 181
2022 General $62,448 155
2021 General $71,915 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Horning
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Russell Horning were reported at $32,336. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Russell Horning Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $71,915 $166 $54–$482 $132
2022 $62,448 $195 $66–$559 $149
2023 $45,022 $233 $82–$673 $160
2024 $42,408 $236 $84–$688 $164
2025 $32,336 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $144,696 212 payments
  2. AbbVie, Inc. $90,246 244 payments
  3. Otsuka America Pharmaceutical, Inc. $6,812 59 payments
  4. Allergan Inc. $4,690 6 payments
  5. Corium, Inc. $1,351 35 payments
  6. Supernus Pharmaceuticals, Inc. $1,164 30 payments
  7. ITI, Inc. $1,152 54 payments
  8. Alkermes, Inc. $596 21 payments
  9. Lundbeck LLC $581 48 payments
  10. Neurocrine Biosciences, Inc. $425 9 payments
  11. Other $2,417 96 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $217,725 145 payments
  2. Travel and Lodging $19,605 117 payments
  3. Food and Beverage $14,848 545 payments
  4. Consulting Fee $1,925 3 payments
  5. Education $27 4 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $144,833 212 payments
  2. VRAYLAR $94,662 237 payments
  3. REXULTI Psychiatry $2,998 27 payments
  4. Azstarys $1,351 35 payments
  5. CAPLYTA $944 35 payments
  6. REXULTI Psychiatry $581 48 payments
  7. INGREZZA $425 9 payments
  8. LOREEV XR $417 24 payments
  9. LYBALVI $381 18 payments
  10. QELBREE $350 23 payments
  11. Other $4,638 201 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,361

Median for Nurse Practitioner: 389

Drug cost

$277,738

Median for Nurse Practitioner: $21,885

Branded share of claims

30.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 91 $147,988
Rexulti Brexpiprazole Brand 31 $64,190
Vraylar Cariprazine Hcl Brand 19 $29,410
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 96 $10,937
Trintellix Vortioxetine Hydrobromide Brand 12 $7,592
Divalproex Sodium Er Divalproex Sodium Brand 27 $2,316
Duloxetine Hcl Generic 55 $1,892
Quetiapine Fumarate Generic 114 $1,520
Hydroxyzine Hcl Generic 15 $992
Modafinil Generic 24 $944

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$20,239

Medicare's payments for the services billed

Medicare patients

24

Average age 65

Services billed

357

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
High blood pressure 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
$33,019 91 —
REXULTI
$2,826 31 —
VRAYLAR
$1,905 19 —
CAPLYTA
$443 — —
Auvelity
$204 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

814 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record